Compare YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF (QDTY) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF vs Sanofi SA — how do they compare? YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF trades at $39.27 (market cap $28.69M), while Sanofi SA trades at $40.07 (market cap $95.18B). The key difference: Sanofi SA is far larger — about 3317.5× YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF's market cap, and Sanofi SA pays a 6.01% dividend while YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF for 61 Days and Sanofi SA for 94 Days on average.
| QDTY | SNY | |
|---|---|---|
Market Cap | $28.69M | $95.18B |
Volume | 22,490 | 2,995,646 |
Sector | Income / Options Overlay | Health |
52-Week High | $46.71 | $52.34 |
52-Week Low | $36.57 | $39.51 |
Typical Hold Time | 61 Days | 94 Days |
Enterprise Value | — | $114.48B |
Dividend Yield | — | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
QDTY trades at $39.27, down 0.84% today, with a bullish technical signal supported by moving averages. The ETF demonstrates strong dividend distribution activity with recent payouts ranging from $0.19 to $0.30 per share, highlighted by a $0.24 dividend announced October 6th, 2026 representing a significant yield. Technical indicators show mixed signals with RSI suggesting potential overbought conditions while overall trend remains positive.
The outlook remains favorable for income-focused investors given the consistent dividend payments, though elevated RSI levels suggest near-term caution. Key risks include market volatility affecting covered call strategies and interest rate sensitivity. The ETF's weekly distribution model provides regular income but requires monitoring of underlying Nasdaq 100 performance for sustainability.
Sanofi (SNY) trades at $40.23, showing minimal daily movement with a 0.07% gain. The stock presents mixed signals with bearish technical indicators but strong fundamental performance, including three consecutive quarterly earnings beats. Recent expansion of the immunology alliance with Regeneron through an $8 billion deal highlights strategic growth initiatives. Valuation metrics show a P/E of 22.14 and P/S of 1.77, while profitability remains solid with a 72.77% gross margin.
SNY offers steady growth potential driven by pipeline expansion and Dupixent momentum, though patent expiration risks loom. Analyst sentiment is cautiously optimistic with 44% buy ratings, but technical weakness and projected 2026 earnings decline present near-term headwinds. The stock represents a balanced opportunity for long-term investors seeking pharmaceutical exposure with manageable risk.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF
QDTY is an actively managed ETF that employs a synthetic covered call strategy on the Nasdaq-100 Index using zero-days-to-expiration (0DTE) options. It aims to generate high weekly income by selling daily call options, providing limited participation in the index's upside while remaining fully exposed to its downside risk.
Read more on QDTY →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
